"These findings are in line with those of the more than 800 patients I've treated personally to date, some of whom are up to seven years post-treatment," said Dr. Katz. "I am excited to see the body of long term data supporting the outcomes of CyberKnife prostate SBRT growing in support of this treatment's benefits for patients."During the press conference, Dr. Katz also spoke to the cost-benefits of CyberKnife SBRT, which he said "is less expensive than IMRT for a payer like Medicare, which can cost the government program upwards of $40,000 for a full round of treatments in some areas." CyberKnife SBRT for patients with intermediate-risk prostate cancer was the focus of a study presented by Robert Meier, M.D., a radiation oncologist with the Swedish Cancer Institute in Seattle, and co-lead by Beth Israel Deaconess Medical Center in Boston. In this multi-center study, 129 patients were treated at 21 centers throughout the United States. At a median follow-up of 36 months, the three-year disease-free survival rate, as updated by Dr. Meier during his presentation, was 99.2 percent, which is higher than those typically seen with external beam radiotherapy. The urinary and rectal side effect profile was as good as or better than other radiotherapy treatments, with comparable sexual function outcomes. "Our study demonstrates very promising cancer control rates and few side effects, which are in line with the growing body of clinical evidence supporting the value of CyberKnife prostate SBRT," said Dr. Meier. "Through the use of image guidance and robotics, we're able to continuously track the prostate and concentrate hundreds of radiation beams into the target with sub-millimeter accuracy, which helps us effectively treat the disease while sparing nearby healthy tissue and critical structures."